Succinobucol

N/A

Report date: 2023/01/14 16:58:28
NME

Base Information

Drug NameSuccinobucol
Drug Alias Name琥珀布可SuccinobucolumAGI-1067AGZ-1067
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLipid peroxidation inhibitorsVascular cell adhesion molecule 1 inhibitors
TargetsVascular cell adhesion molecule 1
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes MellitusAtherosclerosis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFormer Serbia and MontenegroBosnia and HerzegovinaCanada +[10] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAtherogenics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca PlcAtherogenics Inc
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2Diabetes MellitusAtherosclerosis +[6] 

Other Information

ATC CodeN/A
Related LinksKEGG